Navigation Links
TorreyPines Therapeutics Reports Third Quarter 2007 Results
Date:11/14/2007

es' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements, including whether the results of the Phase IIb trial are predictive of results in subsequent trials of tezampanel, whether any preclinical studies or clinical trials, either ongoing or conducted in the future, will prove successful, and if successful, whether the results can be replicated; whether safety and efficacy profiles of any of its drug candidates will be established, or if established, will remain the same, be better or worse in future clinical trials, if any; whether pre-clinical results will be substantiated by ongoing or future clinical trials, if any, or whether any of its drug candidates will be able to improve the signs or symptoms of their respective clinical indication; whether any of its drug candidates will support a filing for marketing approval, will be approved by the regulatory authorities, or if approved, will prove competitive in the market; or whether the necessary financing to support the company's drug development programs will be available. In particular there is no guarantee that clinical trials of any of the company's product candidates will be completed on schedule or that results of these clinical trials will be reported within the anticipated timeframe, that tezampanel will successfully treat migraine pain, that NGX267 will successfully treat the symptoms of cognitive impairment associated with schizophrenia, that NGX267 will successfully treat xerostomia or that TorreyPines will be able to complete the necessary development work and receive regulatory approval for tezampanel or NGX267. These and other risks which may cause results to differ are described in greater detail in the "Risk Factors" section of TorreyPines' annual report on Form 10-K for the year ended December 31,2006 and TorreyPines other SEC reports. The forward-looking statements are based on current information that is lik
'/>"/>
SOURCE TorreyPines Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. TorreyPines Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
2. TorreyPines Therapeutics to Present at ThinkEquitys G5 Conference
3. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
4. TorreyPines Therapeutics to Present at ThinkEquitys ThinkClinic Conference
5. TorreyPines Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
8. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
9. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
10. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
11. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... (Nasdaq: NEOG ) announced today that net ... year, which ended Aug. 31, was $8,883,000 — a ... the first quarter of last year. Adjusted for a ... share in the current quarter were $0.24, compared to ... increased 15% to $67,599,000, from the previous year,s first ...
(Date:9/22/2014)... Sept. 22, 2014  WIRB-Copernicus Group (WCG), the ... services for clinical research, announced today that its ... been reaccredited by the Association for the Accreditation ... to improve safeguards for clinical research participants. ... Deieso , Ph.D., commented, "It is of utmost ...
(Date:9/22/2014)... Olso, Norway (PRWEB) September 22, 2014 ... convenient new parcel and pallet measuring device ... ScanTape™ eliminates manual data entry, offering greater ease ... time savings that result can significantly enhance productivity—an ... in industries where processing volume equals profits. ...
(Date:9/22/2014)... 22, 2014  Spherix Incorporated (SPEX) -- an intellectual property ... property, today announced that the United States Patent & Trademark ... the month of September that is part of a standard ... is: USRE45,121 , Application number: US 13/728,867 ... Dec 27, 2012 The listed inventors of ...
Breaking Biology Technology:Neogen reports 13% net income increase 2Neogen reports 13% net income increase 3Neogen reports 13% net income increase 4Neogen reports 13% net income increase 5Neogen reports 13% net income increase 6Neogen reports 13% net income increase 7Western IRB (WIRB) Awarded AAHRPP Reaccreditation 2ScanTape™ Handheld Dimensioner Increases Processing Volume 2Spherix Notified by United States Patent & Trademark Office of New Standard Essential Patent Issued to Spherix 2Spherix Notified by United States Patent & Trademark Office of New Standard Essential Patent Issued to Spherix 3
... to enable patient care services in Australia through ... retail ... Annual Convention --,Mirixa Corporation, the leader in pharmacy-based patient care ... announced,today that they have signed a definitive technology licensing and ...
... 14 Eli Lilly and Company,(NYSE: LLY ) ... commenced its tender offer for all outstanding,shares of ImClone ... of $70.00,net per share in cash. Lilly and ImClone ... for Lilly to acquire ImClone., The Board of ...
... Management to discuss positive corporate developments and ... call, SANTA CLARA, Calif., Oct. 14 ... cardiac diagnostic and services company, today,announced that ... discuss,recent corporate developments and provide an update ...
Cached Biology Technology:Mirixa Announces Agreement With the Pharmacy Guild of Australia 2Mirixa Announces Agreement With the Pharmacy Guild of Australia 3Lilly Commences Cash Tender Offer for ImClone Systems at $70 Per Share 2Lilly Commences Cash Tender Offer for ImClone Systems at $70 Per Share 3Lilly Commences Cash Tender Offer for ImClone Systems at $70 Per Share 4NewCardio Management to Host Conference Call on October 21 2NewCardio Management to Host Conference Call on October 21 3
(Date:9/22/2014)... 22, 2014) As genetic sequencing technologies continue to ... a critical need to establish appropriate policies and regulatory ... have said. A special policy issue of the ... today and edited by experts with the Center for ... Medicine gives policy makers the tools to jumpstart this ...
(Date:9/22/2014)... their own "antifreeze" proteins to survive in the ... effect, researchers report: The protein-bound ice crystals that ... temperatures warm. , The finding is reported ... of Sciences . , "We discovered what appears ... of antifreeze proteins in Antarctic notothenioid fishes," said ...
(Date:9/22/2014)... captured in this image burn in Khabarovsk Krai, a territory ... red hotspots, accompanied by plumes of smoke mark active fires. ... the east towards the Sea of Okhotsk. Taiga ... swampy forest inhabit the central depression, and deciduous forests are ... are common in Russia in the summer, the 2014 wildfire ...
Breaking Biology News(10 mins):Experts provide much-needed policy analysis for clinical integration of next generation sequencing 2Experts provide much-needed policy analysis for clinical integration of next generation sequencing 3Study: Antifreeze proteins in Antarctic fishes prevent freezingand melting 2Study: Antifreeze proteins in Antarctic fishes prevent freezingand melting 3
... Investigating the building blocks for next-generation computer memory ... third Tier One research award. Vassiliy Lubchenko, ... selected as a 2011 Alfred P. Sloan Research Fellow ... his field. Drawn from 54 colleges and universities in ...
... Census of Marine Life, a 10-year scientific initiative to assess ... the global ocean, succeed when similar efforts have failed? ... David Penman, former Chair of the Governing Board of the ... from the Census of Marine Life." The briefing will be ...
... 9, 2011) -- High in the sky, water in clouds ... as sulfur dioxide into reactive aqueous particulates. Although this behavior ... the University of Oregon provides evidence that it should be. ... volcanic gasses and many combustion processes -- in acid rain ...
Cached Biology News:UH chemist investigates material for next-generation computer memory 2Lessons learned from the 10-year Census of Marine Life to be presented 2Researchers get new view of how water and sulfur dioxide mix 2
...
...
Kit for testing the ability of a compound to simulate lipolysis in cultured human adipocytes. Kit contains controls, buffers and reagents for detecting glycerol and non-esterified free fatty acids. A...
The strip cap tool is a used for properly seating 8- and 12-cap strips in microplates or strip tubes. A grooved channel on one side is designed to seat domed caps, while the flat edge on the opposite...
Biology Products: